MA50482A - Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b - Google Patents

Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b

Info

Publication number
MA50482A
MA50482A MA050482A MA50482A MA50482A MA 50482 A MA50482 A MA 50482A MA 050482 A MA050482 A MA 050482A MA 50482 A MA50482 A MA 50482A MA 50482 A MA50482 A MA 50482A
Authority
MA
Morocco
Prior art keywords
sulfamoylarylamide
hepatitis
cycling
derivatives
treatment
Prior art date
Application number
MA050482A
Other languages
English (en)
Inventor
Samuël Dominique Demin
Sandrine Céline Grosse
Geerwin Yvonne Paul Haché
Lili Hu
Stefaan Julien Last
Serge Maria Aloysius Pieters
Pierre Jean-Marie Bernard Raboisson
Geert Rombouts
Koen Vandyck
Sandrine Marie Helene Vendeville
Wim Gaston Verschueren
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA50482A publication Critical patent/MA50482A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
MA050482A 2015-07-02 2016-07-01 Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b MA50482A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15175021 2015-07-02
EP15189903 2015-10-15
EP15201332 2015-12-18
EP16157726 2016-02-26

Publications (1)

Publication Number Publication Date
MA50482A true MA50482A (fr) 2020-09-02

Family

ID=56289521

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050482A MA50482A (fr) 2015-07-02 2016-07-01 Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
MA42292A MA42292B1 (fr) 2015-07-02 2016-07-01 Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA42292A MA42292B1 (fr) 2015-07-02 2016-07-01 Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b

Country Status (37)

Country Link
US (2) US10875876B2 (fr)
EP (2) EP3590943A1 (fr)
JP (1) JP6914201B2 (fr)
KR (1) KR20180022818A (fr)
CN (1) CN107735400B (fr)
AU (1) AU2016287472B2 (fr)
BR (1) BR112017028504A2 (fr)
CA (1) CA2986344A1 (fr)
CL (1) CL2017003459A1 (fr)
CO (1) CO2017012268A2 (fr)
CR (1) CR20180069A (fr)
CY (1) CY1122688T1 (fr)
DK (1) DK3317286T3 (fr)
EA (1) EA036629B1 (fr)
ES (1) ES2759775T3 (fr)
GE (1) GEP20207117B (fr)
HK (1) HK1253337B (fr)
HR (1) HRP20191901T1 (fr)
HU (1) HUE046283T2 (fr)
IL (2) IL256392A (fr)
MA (2) MA50482A (fr)
MD (1) MD3317286T2 (fr)
MX (2) MX376433B (fr)
NI (1) NI201700169A (fr)
PE (1) PE20180410A1 (fr)
PH (1) PH12017502316A1 (fr)
PL (1) PL3317286T3 (fr)
PT (1) PT3317286T (fr)
RS (1) RS59609B1 (fr)
SG (1) SG10202002302UA (fr)
SI (1) SI3317286T1 (fr)
SM (1) SMT201900672T1 (fr)
TN (1) TN2017000535A1 (fr)
TW (1) TWI705058B (fr)
UA (1) UA124054C2 (fr)
UY (1) UY36766A (fr)
WO (1) WO2017001655A1 (fr)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
SG10201913880XA (en) 2015-07-02 2020-03-30 Hoffmann La Roche Bicyclic lactams and methods of use thereof
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
BR112019007450A2 (pt) 2016-10-14 2020-07-07 Precision Biosciences, Inc. meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b
WO2018073193A1 (fr) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Lactames de pyridone bicycliques et leurs méthodes d'utilisation
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
WO2018153326A1 (fr) * 2017-02-22 2018-08-30 上海长森药业有限公司 Composé de sulfonyle hydrazine et son utilisation
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
KR20200083552A (ko) 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드
CN111448199A (zh) 2017-11-02 2020-07-24 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新的高活性的氨基-噻唑取代的吲哚-2-甲酰胺
CN111315749A (zh) 2017-11-17 2020-06-19 诺华股份有限公司 新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途
EP3721402A4 (fr) 2017-12-05 2021-08-04 Rapidsos Inc. Contenu de média social pour gestion d'urgence
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
EP3728282B1 (fr) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Dinucléotides 2'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting
CA3091142C (fr) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Composes de pyrrolizine substitues et utilisations connexes
EP3759110A1 (fr) 2018-02-28 2021-01-06 Novartis AG Composés d'indole-2-carbonyle et leur utilisation dans le traitement de l'hépatite b
BR112020018601A2 (pt) 2018-03-14 2020-12-29 Janssen Sciences Ireland Unlimited Company Regime de dosagem de modulador de montagem de capsídeo
WO2019195181A1 (fr) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
EP3781571B1 (fr) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG Dérivés de n-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide et composés similaires en tant qu'inhibiteurs de la kinase rip1 pour le traitement p.e. du syndrome de l'intestin irritable (sii)
WO2019211799A1 (fr) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle
CN110437232B (zh) * 2018-05-04 2022-04-12 上海长森药业有限公司 双并环脲类核衣壳抑制剂及其药物用途
AU2019284617A1 (en) 2018-06-11 2021-01-28 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
EP3597653A1 (fr) 2018-07-19 2020-01-22 Irbm S.P.A. Inhibiteurs cycliques du virus de l'hépatite b
EP3597637A1 (fr) 2018-07-19 2020-01-22 Irbm S.P.A. Inhibiteurs du virus de l'hépatite b
TWI826492B (zh) * 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
WO2020028097A1 (fr) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique
EP3608326A1 (fr) 2018-08-10 2020-02-12 Irbm S.P.A. Inhibiteurs tricycliques du virus de l'hépatite b
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US10977927B2 (en) 2018-10-24 2021-04-13 Rapidsos, Inc. Emergency communication flow management and notification system
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
US20220009945A1 (en) 2018-11-02 2022-01-13 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv)
UY38435A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
CN111434665B (zh) * 2019-01-11 2023-03-10 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
US11033556B2 (en) 2019-02-14 2021-06-15 Aligos Therapeutics, Inc. Bicyclic sulfonamides
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (fr) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting
EP3934757B1 (fr) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Dinucléotides cycliques en 2'3' et leurs promédicaments
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
SG11202111236UA (en) 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
US20220227789A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
MX2021013105A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb).
PH12021552749A1 (en) 2019-04-30 2022-07-11 Aicuris Gmbh & Co Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
TW202108576A (zh) 2019-05-06 2021-03-01 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物
UY38705A (es) 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
EP3825318A1 (fr) 2019-11-25 2021-05-26 Promidis S.r.l. Inhibiteurs tricycliques du virus de l'hépatite b oxalamido-substitués
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
EP3741762A1 (fr) 2019-05-23 2020-11-25 Irbm S.P.A. Inhibiteurs tricycliques du virus de l'hépatite b oxalamido-substitués
AU2020281802A1 (en) * 2019-05-28 2021-11-25 Janssen Sciences Ireland Unlimited Company Azepines as HBV capsid assembly modulators
US20220305116A1 (en) 2019-06-18 2022-09-29 Janssen Sciences lreland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
EP4017476A1 (fr) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Formulations pharmaceutiques de ténofovir alafénamide
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
ES3022990T3 (en) 2019-12-06 2025-05-29 Prec Biosciences Inc Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN115551870B (zh) * 2020-02-11 2025-08-08 圣拉斐尔医院有限公司 乙型肝炎病毒的螺环抑制剂
EP3865489A1 (fr) 2020-02-11 2021-08-18 Promidis S.r.l. Inhibiteurs spirocycliques du virus de l'hépatite b
EP3985010A1 (fr) 2020-10-14 2022-04-20 Promidis S.r.l. Inhibiteurs spirocycliques du virus de l'hépatite b
TWI845826B (zh) 2020-03-20 2024-06-21 美商基利科學股份有限公司 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
MX2023001507A (es) 2020-08-07 2023-03-06 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico.
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN115160344A (zh) * 2021-04-06 2022-10-11 上海长森药业有限公司 通过口服给药抑制CD4+Treg细胞的药物和方法
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359415A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN117777047B (zh) * 2024-02-26 2024-04-30 四川大学 N-取代氮杂螺癸单烯酮类化合物及其制备方法和应用
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (fr) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Polythérapies avec de la ribavirine
WO2025240242A1 (fr) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Polythérapies avec ribavirine
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
WO1984003281A1 (fr) 1983-02-19 1984-08-30 Beecham Group Plc Derives anylides et benzamides d'azabicycloalkyle
JPS62142164A (ja) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd ４，５−ジクロロイミダゾ−ル系化合物及びそれらを含有する有害生物防除剤
IN164880B (fr) 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (fr) 1987-03-13 1997-07-29 Rikuo Nasu Derives de l'imidazole et compositions a base de ces derives pour l'elimination d'organismes nuisibles
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JPH10504525A (ja) 1994-05-27 1998-05-06 ジェイムズ・ブラック・ファウンデーション・リミテッド ガストリンとｃｃｋ拮抗薬
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
WO1997049695A1 (fr) 1996-06-25 1997-12-31 Smithkline Beecham P.L.C. Derives de sulfonamide utilises comme antagonistes du recepteur 5ht7
AU5127098A (en) 1996-11-29 1998-06-22 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
ES2317688T3 (es) 1998-01-29 2009-04-16 Amgen Inc. Moduladores ppar-gamma.
HUP0101275A3 (en) 1998-03-26 2002-12-28 Japan Tobacco Inc Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
BR0007527B1 (pt) 1999-01-15 2011-12-27 fenilfenantridinas com atividade inibitària de pde-iv, seu uso, bem como medicamento compreendendo as mesmas.
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
HK1046869A1 (zh) 1999-08-10 2003-01-30 The Chancellor, Masters And Scholars Of The University Of Oxford 使用长链n烷基化合物及其恶衍生物作为抗病毒成分
BR0014076A (pt) 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
WO2001055121A1 (fr) 2000-01-28 2001-08-02 Kaken Pharmaceutical Co., Ltd. Dérivés d'azépine
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (fr) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Dérivés de sulfonamide pharmaceutiquement actifs comportant des groupes lipophiles ainsi que ionisables comme inhibiteurs de protéine junkinases
WO2002051410A2 (fr) 2000-12-22 2002-07-04 Akzo Nobel N.V. Derives de phenylthiazole et thiazoline et leur utilisation comme antiparasites
EP1357123B8 (fr) 2000-12-27 2006-02-01 Dainippon Sumitomo Pharma Co., Ltd. COMPOSES DE CARBAPENEM, médicament et antibactérien les comprenant , et leurs usages.
AU2002248418A1 (en) 2001-02-09 2002-08-28 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (de) 2001-07-25 2003-02-13 Degussa Verfahren zur Herstellung von modifiziertem Ruß
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
DE60204718T2 (de) 2001-11-20 2006-05-18 Eli Lilly And Co., Indianapolis 3-substituierte oxindol beta 3 agonisten
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
AU2003242127A1 (en) 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
WO2004002481A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Activateurs de la glycokinase
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1541172A1 (fr) 2002-08-09 2005-06-15 Ajinomoto Co., Inc. Remede contre les maladies intestinales et les douleurs viscerales
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
PL377087A1 (pl) 2002-09-06 2006-01-23 Janssen Pharmaceutica, N.V. Związki heterocykliczne
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
EP1590327A1 (fr) 2002-12-23 2005-11-02 Millennium Pharmaceuticals, Inc. Inhibiteurs du ccr8
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
JP4969238B2 (ja) 2003-03-27 2012-07-04 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CA2523743A1 (fr) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Acides carboxyliques substitues par des heterocycles
US7592352B2 (en) 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
JP2007501859A (ja) 2003-05-13 2007-02-01 シェーリング　コーポレイション γ−セクレターゼ阻害剤としての架橋ｎ−アリールスルホニルピペリジン
WO2005007621A2 (fr) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Inhibiteurs de ligase d'ubiquitine
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
US20060122173A1 (en) 2003-06-06 2006-06-08 Jakob Busch-Petersen Il-8 receptor antagonists
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP1678147B1 (fr) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2005087217A1 (fr) 2004-03-05 2005-09-22 The General Hospital Corporation Compositions et procedes pour moduler l'interaction entre des polypeptides
JP2007536344A (ja) 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
US20090105218A1 (en) 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use
US7750158B2 (en) 2004-06-22 2010-07-06 Schering Corporation Cannabinoid receptor ligands
JP4703649B2 (ja) 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド 薬学的因子としてのピロール誘導体
BRPI0514691A (pt) 2004-08-31 2008-06-17 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
DE102004042441A1 (de) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2005295788A1 (en) 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
MX2007004699A (es) 2004-10-19 2007-06-14 Novartis Vaccines & Diagnostic Derivados de indol y bencimidazol.
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
CA2589773A1 (fr) 2004-12-22 2006-06-29 Astrazeneca Ab Derives de pyridinecarboxamide employes en tant qu'agents anticancereux
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
FI117653B (fi) 2005-02-21 2006-12-29 Eigenor Oy Menetelmä ja laitteisto liikkuvien kohteiden havaitsemiseksi tutkalla
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2006128129A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Traitement anticancereux
WO2006128172A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Procede pour traiter des troubles auto-immuns regules par des lymphocytes b
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
HRP20100542T1 (hr) 2005-09-16 2010-11-30 Arrow Therapeutics Limited Derivati bifenila i njihova uporaba za liječenje hepatitisa c
CN101331116A (zh) 2005-12-12 2008-12-24 健亚生物科技公司 N-(6-元芳香环)酰胺基抗病毒化合物
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
WO2007073935A1 (fr) 2005-12-29 2007-07-05 Lek Pharmaceuticals D.D. Composes heterocycliques
WO2007131168A2 (fr) 2006-05-04 2007-11-15 Institute For Hepatitis And Virus Research Inhibiteurs de la sécrétion d'antigènes du virus de l'hépatite b destinés au traitement d'un virus de l'hépatite chronique
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
US20100016310A1 (en) 2006-08-17 2010-01-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
AU2007314521A1 (en) 2006-10-06 2008-05-08 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
EP2091527B1 (fr) 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Analogues de sulfure, sulfoxyde et sulfone de chalcone, leurs dérivés et leurs utilisations thérapeutiques
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
JP2008184403A (ja) 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
SG182205A1 (en) 2007-03-15 2012-07-30 Novartis Ag Organic compounds and their uses
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
US8338417B2 (en) 2007-05-04 2012-12-25 Irm Llc Compounds and compositions as c-kit and PDGFR kinase inhibitors
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
KR20100039429A (ko) 2007-08-02 2010-04-15 에프. 호프만-라 로슈 아게 Ｃｎｓ 질환의 치료를 위한 벤즈아미드 유도체의 용도
CN101429166B (zh) 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2009146013A1 (fr) 2008-03-31 2009-12-03 Georgetown University Inhibiteurs de phosphatase de chaîne légère de myosine
ES2527589T3 (es) 2008-04-24 2015-01-27 Msd K.K. Inhibidor de la enzima de elongación de ácidos grasos de cadena larga que comprende un derivado de arilsulfonilo como principio activo
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US8299096B2 (en) 2008-06-26 2012-10-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2010018113A2 (fr) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryle aminotétralines
US9040488B2 (en) 2008-09-02 2015-05-26 Baruch S. Blumberg Institute Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (fr) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Inhibiteurs de la lipase destinés à être utilisés dans le traitement de l’obésité
ES2548141T3 (es) 2008-11-20 2015-10-14 Glaxosmithkline Llc Compuestos químicos
US20100204210A1 (en) 2008-12-04 2010-08-12 Scott Sorensen Method for treating pulmonary diseases using rho kinase inhibitor compounds
CA2748174A1 (fr) 2008-12-30 2010-07-08 Arqule, Inc. Composes de 1h-pyrazolo-[3,4-d]pyrimidine-6-amines substituees
WO2010088000A2 (fr) 2009-02-02 2010-08-05 Angion Biomedica Corp. Composés antifibrotiques et leurs utilisations
WO2010123139A1 (fr) 2009-04-24 2010-10-28 持田製薬株式会社 Dérivé arylcarboxamide ayant un groupe sulfamoyle
BRPI1010909A2 (pt) 2009-05-19 2015-09-08 Bayer Cropscience Ag "inseticida arilpirrolinas"
CA3184380A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
WO2011002635A1 (fr) 2009-06-30 2011-01-06 Siga Technologies, Inc. Traitement et prévention d'infections par le virus de la dengue
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011035143A2 (fr) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Procédés et compositions pour inhiber des maladies et des états à médiation par rho
WO2011058766A1 (fr) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Dérivés d'arylcarboxamide comme bloqueurs de ttx-s
CN102093320B (zh) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 一种可溶性环氧化物水解酶抑制剂
EP2523936A1 (fr) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Composés qui modulent le récepteur cb2
WO2011088561A1 (fr) 2010-01-20 2011-07-28 University Of Manitoba Composés antiviraux et compositions
WO2011109237A2 (fr) 2010-03-02 2011-09-09 Emory University Utilisations de la noscapine et de ses dérivés chez des patients diagnostiqués avec la polypose adénomateuse familiale (fap)
EP2545042A1 (fr) 2010-03-11 2013-01-16 Bristol-Myers Squibb Company Composés utilisables pour le traitement de l'hépatite c
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
EP2552208A4 (fr) 2010-03-31 2014-07-09 Glaxo Group Ltd Imidazolyl-imidazoles en tant qu'inhibiteurs de kinase
PT2566327T (pt) 2010-05-07 2017-05-26 Glaxosmithkline Llc Indoles
EP2580190A4 (fr) 2010-06-11 2014-04-16 Goeran Wadell Nouveaux composés antiviraux
US20130142827A1 (en) 2010-06-25 2013-06-06 Philadelphia Health & Education Corporation D/B/A Induction of immune response
BR112013001125A2 (pt) 2010-07-19 2016-05-17 Inspire Pharmaceuticals Inc compostos inibidores de rho cinase bifuncionais, composição e uso
EP2598478A2 (fr) 2010-07-26 2013-06-05 Neurotherapeutics Pharma, Inc. Dérivés d'arylsulfonamide, compositions en contenant et leurs méthodes d'utilisation
MX2013001003A (es) 2010-07-27 2013-03-07 Inspire Pharmaceuticals Inc Compuestos inhibidores de quinasa, en formato de profarmaco, para tratar enfermedades oftalmicas.
WO2012016133A2 (fr) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
WO2012033956A1 (fr) 2010-09-08 2012-03-15 Mithridion, Inc. Composés et compositions améliorant la cognition, méthodes de préparation et méthodes de traitement
WO2012047856A2 (fr) 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Nouveaux inhibiteurs de la sécrétion d'antigènes du virus de l'hépatite b
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP2646439B1 (fr) 2010-12-02 2016-05-25 Bristol-Myers Squibb Company Amides d'alkyle comme inhibiteurs d'attachement du vih
WO2012080050A1 (fr) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Formes solides d'un composé de phénoxybenzènesulfonyle
GB201103419D0 (fr) 2011-02-28 2011-04-13 Univ Aberdeen
LT3590928T (lt) 2011-04-08 2021-08-25 Janssen Sciences Ireland Unlimited Company Pirimidino dariniai, skirti virusinės infekcijos gydymui
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
JP5977347B2 (ja) 2011-07-01 2016-08-24 バルーク エス．ブルームバーグ インスティテュート Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
AU2013207205B2 (en) 2012-01-06 2017-02-02 Janssen Sciences Ireland Uc 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B
BR112014021498A2 (pt) 2012-02-29 2017-07-18 Institute For Hepatitis And Virus Res composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
MX2014011749A (es) 2012-03-31 2015-01-22 Hoffmann La Roche 4-metil-dihidropirimidinas novedosas para el tratamiento y la prolifaxis de la infeccion por el virus de la hepatitis b.
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ES2597757T3 (es) 2012-05-25 2017-01-20 Janssen Sciences Ireland Uc Nucleósidos de uracilespirooxetano
JP6431478B2 (ja) 2012-06-01 2018-11-28 ドレクセル ユニバーシティ Ｂ型肝炎ウイルスのｃｃｃｄｎａの転写の調節
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CN104797561B (zh) 2012-08-28 2017-03-01 爱尔兰詹森科学公司 稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途
EP2892893B2 (fr) 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
SG10201803698UA (en) 2012-12-27 2018-06-28 Univ Drexel Novel antiviral agents against hbv infection
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
TWI622592B (zh) 2013-02-28 2018-05-01 衛材Ｒ＆Ｄ企管股份有限公司 四氫咪唑並［１，５－ｄ］［１，４］氧氮雜卓衍生物
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EP2970340B1 (fr) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CN105209470B (zh) 2013-05-17 2018-02-06 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶
CN105744838B (zh) 2013-05-28 2017-12-08 拜耳作物科学股份公司 作为农药的杂环化合物
BR112015029455A8 (pt) 2013-05-28 2020-03-17 Astrazeneca Ab compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer
WO2014198880A1 (fr) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. Composés 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-diones ayant une activité agoniste des récepteurs des orexines de type 2
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015057945A1 (fr) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Effecteurs d'assemblage de virus de l'hépatite b
WO2015055764A1 (fr) 2013-10-18 2015-04-23 Syngenta Participations Ag Dérivés de 3-méthanimidamid-pyridine utilisés comme fongicides
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
KR20160127714A (ko) 2013-11-14 2016-11-04 노비라 테라퓨틱스, 인코포레이티드 아제판 유도체 및 b형 간염 감염의 치료 방법
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
DK3498692T3 (da) 2014-01-31 2022-05-16 Cognition Therapeutics Inc Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
KR101926243B1 (ko) 2014-03-07 2018-12-06 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 및 예방을 위한 6-융합된 헤테로아릴다이하이드로피리미딘
AU2015229174B2 (en) 2014-03-13 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein allosteric modulators
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
JP2017512789A (ja) 2014-03-28 2017-05-25 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． ジヒドロピリミジン化合物及び医薬におけるその適用
AU2015266481B2 (en) 2014-05-30 2018-06-07 Qilu Pharmaceuticals Co., Ltd. Dihydropyrimido fused ring derivative as HBV inhibitor
ES2802412T3 (es) 2014-12-02 2021-01-19 Novira Therapeutics Inc Compuestos de sulfonamida inversa a base de sulfuro, alquilo y piridilo para el tratamiento del VHB
WO2016109684A2 (fr) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Dérivés et méthodes de traitement d'infections provoquées par le virus de l'hépatite b
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
CA2980298A1 (fr) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Derives d'azocane et d'azonane, et methodes de traitement d'infections provoquees par le virus de l'hepatite b
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10273228B2 (en) 2015-04-17 2019-04-30 Indiana University Research And Technology Corporation Hepatitis B viral assembly effectors
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
CN109251212A (zh) 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
MA42292A (fr) 2018-05-09
PE20180410A1 (es) 2018-03-01
PL3317286T3 (pl) 2020-03-31
PH12017502316A1 (en) 2018-06-25
CR20180069A (es) 2018-06-27
HUE046283T2 (hu) 2020-02-28
HK1253337B (en) 2020-05-08
NI201700169A (es) 2018-08-01
SMT201900672T1 (it) 2020-01-14
US20170002025A1 (en) 2017-01-05
HRP20191901T1 (hr) 2020-01-24
MX2020010737A (es) 2020-11-09
TN2017000535A1 (en) 2019-04-12
GEP20207117B (en) 2020-06-10
MX376433B (es) 2025-03-07
RS59609B1 (sr) 2020-01-31
CN107735400A (zh) 2018-02-23
US10875876B2 (en) 2020-12-29
JP2018524333A (ja) 2018-08-30
IL276333B (en) 2021-07-29
MX2017016781A (es) 2018-07-06
CN107735400B (zh) 2021-02-02
BR112017028504A2 (pt) 2018-08-28
KR20180022818A (ko) 2018-03-06
CL2017003459A1 (es) 2018-05-11
SG10202002302UA (en) 2020-05-28
EP3590943A1 (fr) 2020-01-08
US20210179635A1 (en) 2021-06-17
TW201713635A (zh) 2017-04-16
MA42292B1 (fr) 2019-12-31
IL276333A (en) 2020-09-30
SI3317286T1 (sl) 2020-02-28
PT3317286T (pt) 2019-12-09
CA2986344A1 (fr) 2017-01-05
AU2016287472B2 (en) 2020-11-05
EA036629B1 (ru) 2020-12-01
EP3317286B1 (fr) 2019-09-11
UY36766A (es) 2016-12-30
DK3317286T3 (da) 2019-12-02
HK1250031A1 (zh) 2018-11-23
HK1253337A1 (en) 2019-06-14
JP6914201B2 (ja) 2021-08-04
WO2017001655A1 (fr) 2017-01-05
EA201890200A1 (ru) 2018-06-29
CY1122688T1 (el) 2021-03-12
UA124054C2 (uk) 2021-07-14
EP3317286A1 (fr) 2018-05-09
AU2016287472A1 (en) 2017-11-30
TWI705058B (zh) 2020-09-21
ES2759775T3 (es) 2020-05-12
CO2017012268A2 (es) 2018-05-31
IL256392A (en) 2018-02-28
MD3317286T2 (ro) 2019-12-31

Similar Documents

Publication Publication Date Title
MA50482A (fr) Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
EP3233878A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA45550A (fr) Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3474863A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
EP3353841A4 (fr) Procédé de préparation et d'application de composites de carbone-sélénium
EP3390357A4 (fr) Composés de biarylmonobactame et procédés d'utilisation correspondants pour le traitement d'infections bactériennes
GB201720163D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3317274A4 (fr) Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux
EP2953456A4 (fr) Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
MA52253A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
ME03078B (fr) Dérivés de sulfonylpipéridine et leur utilisation pour le traitement de maladies médiées par une prokinéticine
EP2870161A4 (fr) Oxabicycloheptanes et oxabicycloheptènes pour le traitement d'une lésion de reperfusion
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP2953462A4 (fr) Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d'infections
EP3626256C0 (fr) Composition pour le traitement des lésions tissulaires